Type 2 diabetes is a progressive condition in which the body becomes resistant to the normal effects of insulin and/or gradually loses the capacity to produce enough insulin in the pancreas. We do not know what causes type 2 diabetes. Type 2 diabetes is associated with modifiable lifestyle risk factors. Type 2 diabetes also has strong genetic and family related risk factors.
The dramatic increase in the prevalence, progressive nature and diagnosis of type 2 diabetes is the main driver of this rapid growth rate. The rise in disease-related comorbidities has also fuelled a more aggressive approach to treatment, including the use of multiple-drug therapies.
The Americas dominated the global type 1 diabetes drug market and accounted for close to 50% of the global type 1 diabetes market size. The US was the largest revenue contributor to the diabetes drug market in this region because of the growing prevalence of the disease and rise in obesity. The accessibility to therapies by reimbursement programs is further expected to drive the growth of the diabetes drug market size in the Americas.
In 2019, the market size of Type 2 Diabetes is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Type 2 Diabetes.
This report studies the global market size of Type 2 Diabetes, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Type 2 Diabetes sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.
In global market, the following companies are covered:
Novo Nordisk
Sanofi
Merck
Eli Lily
AstraZeneca
Astellas Pharma
Daiichi Sankyo
Biocon
Boehringer Ingelheim
Market Segment by Product Type
Insulins
DPP-4 Inhibitors
GLP-1 Receptor Agonists
SGLT-2 Inhibitors
Market Segment by Application
Drugstore
Hospital
Others
Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)
The study objectives are:
To analyze and research the Type 2 Diabetes status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Type 2 Diabetes manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
In this study, the years considered to estimate the market size of Type 2 Diabetes are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
Summary:
Get latest Market Research Reports on Type 2 Diabetes . Industry analysis & Market Report on Type 2 Diabetes is a syndicated market report, published as Global (United States, European Union and China) Type 2 Diabetes Market Research Report 2019-2025. It is complete Research Study and Industry Analysis of Type 2 Diabetes market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.